Exploring des‐acyl ghrelin's influence on the expression of RBP4, which has been shown to reduce insulin sensitivity, leading to diabetes, revealed that des‐acyl ghrelin treatment of C2C12 cells leads to a time‐ and dose‐dependent increase in the mRNA levels of RBP4 (Figure 4a,b). Here, RBP4 is linked to diabetes mellitus.